Trisectionectomies (TS) dramatically enhance overall and disease-free survival for patients with Bismuth-Corlette type II and III perihilar cholangiocarcinoma, outperforming standard hemihepatectomies (EH). In a study of 443 patients, TS improved overall survival to 52.4 months compared to 31 months for EH. Although TS resulted in higher rates of liver failure, morbidity and mortality rates remained similar between the two surgical approaches. Consider TS as a vital option when feasible.
Journal Article by Tzedakis S, Dhote A (…) Boudjema K et 23 al. in Ann Surg
Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.